Baseline clinical and laboratory variables in 1193 SCD patients
| Variable . | Value . |
|---|---|
| Age at first encounter, median (IQR), y | 24 (17-35) |
| Sex, male/female, n (%) | 515 (43.2)/678 (56.8) |
| Race, African American, n (%) | 1123 (94.1) |
| Sickle cell genotype, n (%) | |
| HbSS/SB0-thalassemia | 831 (69.7) |
| HbSC | 290 (24.3) |
| HbSB+-thalassemia | 69 (5.8) |
| Other | 3 (0.3) |
| Hydroxyurea by sickle cell genotype, n/N (%) | |
| Total | 659/1193 (55.2) |
| HbSS/SB0- thalassemia | 560/831 (67.4) |
| HbSC | 77/290 (26.6) |
| HbSB+-thalassemia | 22/69 (31.9) |
| Other | 0/3 (0) |
| Variable . | Value . |
|---|---|
| Age at first encounter, median (IQR), y | 24 (17-35) |
| Sex, male/female, n (%) | 515 (43.2)/678 (56.8) |
| Race, African American, n (%) | 1123 (94.1) |
| Sickle cell genotype, n (%) | |
| HbSS/SB0-thalassemia | 831 (69.7) |
| HbSC | 290 (24.3) |
| HbSB+-thalassemia | 69 (5.8) |
| Other | 3 (0.3) |
| Hydroxyurea by sickle cell genotype, n/N (%) | |
| Total | 659/1193 (55.2) |
| HbSS/SB0- thalassemia | 560/831 (67.4) |
| HbSC | 77/290 (26.6) |
| HbSB+-thalassemia | 22/69 (31.9) |
| Other | 0/3 (0) |